DNLI - デナリ・セラピュ―ティクス (Denali Therapeutics Inc.)

DNLIのニュース

   Denali Therapeutics (DNLI) Presents At Goldman Sachs 42nd Annual Global Healthcare Conference - Slideshow  2021/06/10 19:11:20 Seeking Alpha
   Denali Therapeutics Inc (DNLI): Price Now Near $70.67; Daily Chart Shows Downtrend on 100 Day Basis  2021/06/08 15:09:35 ETF Daily News
Regarding the trend, note that the strongest trend exists on the 50 day timeframe. The post Denali Therapeutics Inc (DNLI): Price Now Near $70.67; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .
   Denali Therapeutics (DNLI ) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow  2021/06/03 00:19:31 Seeking Alpha
   Denali Therapeutics (DNLI) Presents At UBS 2021 Global Healthcare Virtual Conference - Slideshow  2021/05/25 19:18:34 Seeking Alpha
   Tao Capital Management LP Buys Denali Therapeutics Inc, Sells Tesla Inc, Uber Technologies Inc, ...  2021/05/18 18:38:33 GuruFocus
Related Stocks: DNLI ,
   Eli Lilly bolsters neuro, immunology pipeline via multi-drug alliance with Rigel - MedCity News  2021/02/18 17:28:37 MedCity News
Eli Lilly is paying $125 million up front to team up with Rigel Pharmaceuticals on drugs that block a signaling protein involved in inflammation. With the alliance, Lilly joins Sanofi and Denali Therapeutics in the pursuit of drugs that block this protein.
   STAT+: Experts encouraged by Denali’s early results in study of Hunter syndrome drug  2021/02/12 12:29:32 STAT News
A preliminary study of a medicine developed by Denali Therapeutics to treat Hunter syndrome, a rare genetic disease, has left outside experts encouraged by its potential.
   Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Sells 1,470 Shares of Stock  2021/02/12 02:26:58 Watchlist News
Denali Therapeutics Inc. (NASDAQ:DNLI) insider Carole Ho sold 1,470 shares of the business’s stock in a transaction dated Tuesday, February 9th. The stock was sold at an average price of $74.68, for a total value of $109,779.60. Following the sale, the insider now owns 1,476 shares in the company, valued at approximately $110,227.68. The transaction […]
   Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors  2021/01/11 13:30:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad…
   Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration  2021/01/08 13:30:00 GlobeNewswire
Late-breaker presentation on 12-week data from Cohort A in Phase 1/2 study of DNL310 (ETV:IDS) in Hunter syndrome (MPS II) to be held at WORLD Symposium on…
   Biogen reports 11.16% passive stake in Denali Therapeutics (NASDAQ:DNLI)  2020/09/28 20:37:54 Seeking Alpha
Biogen purchases ~13.3M shares of Denali Therapeutics (NASDAQ:DNLI) on September 22. This represents 11.16% of total shares outstanding. The stake does not
   The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO  2020/09/17 11:59:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Myokardia Inc (NASDAQ: MYOK ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Revance Therapeutics Inc (NASDAQ: RVNC ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 16) PainReform Ltd (NASDAQ: PRFX ) Pandion Therapeutics Inc (NASDAQ: PAND ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Moderna Announces 2 R&D Collaborations For Up To $880M Moderna Inc (NASDAQ: MRNA ) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) announced a three-year strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for cystic fibrosis.
   The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO  2020/09/16 12:00:28 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than doubled on its Wall Street debut) Repare Therapeutics Inc (NASDAQ: RPTX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) Histogen Inc (NASDAQ: HSTO ) PainReform Ltd (NASDAQ: PRFX ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Roche Gets Label Expansion For Cancer Screening Test Roche Holdings AG Basel (OTC: RHHBY ) announced FDA approval for the expanded use of CINtec PLUS Cytology, its first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus.
   The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO  2020/09/15 11:55:39 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Stoke Therapeutics Inc (NASDAQ: STOK ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 14) Acorda Therapeutics Inc (NASDAQ: ACOR ) AEterna Zentaris Inc. (NASDAQ: AEZS ) BELLUS Health Inc (NASDAQ: BLU ) PainReform Ltd (NASDAQ: PRFX ) Predictive Oncology Inc (NASDAQ: POAI ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Marinus Reports Positive Late-Stage Readout In Epilepsy Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) announced positive top-line results from its registrational Phase 3 clinical trial, dubbed Marigold, evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder, a rare, genetic epilepsy with refractory seizures.
   MedGenome announces Strategic Collaboration in Parkinson's Disease with Denali Therapeutics  2020/08/26 09:00:00 PR Newswire
FOSTER CITY, California, Aug. 26, 2020 /PRNewswire/ -- MedGenome, a leading genomic diagnostics, research and data company based in Foster City, CA and Bangalore, India, today announced that it has formed a strategic discovery collaboration focused on novel discoveries in Parkinson's…

calendar